Oragenics Inc OGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.56
- Day Range
- $0.56–0.58
- 52-Week Range
- $0.50–1.49
- Bid/Ask
- $0.55 / $0.58
- Shares Outstanding
- 4.51M
- Market Cap
- $2.52M
- Volume/Avg
- 24,019 / 48,739
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3
- Website
- https://www.oragenics.com
Valuation
|
Metric
|
OGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OGEN
|
|---|---|
Quick Ratio | 4.67 |
Current Ratio | 5.73 |
Interest Coverage | −16.27 |
Quick Ratio
OGEN
Profitability
|
Metric
|
OGEN
|
|---|---|
Return on Assets (Normalized) | −126.61% |
Return on Equity (Normalized) | −205.90% |
Return on Invested Capital (Normalized) | −154.31% |
Return on Assets
OGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%Sj^<vR | LOCK|@Xslj | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vcRRSkP | LOCK|l^Cl | $70B | |||
| argenx SE ADR
ARGX
| LOCK|X$G<&J! | LOCK|K^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vcX<bSf | LOCK|@kJ$K | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ScTw?^? | LOCK|%^ | $37B | |||
| Moderna Inc
MRNA
| LOCK|$$<>p$& | LOCK|m>> | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tVQ#B&& | LOCK|nt^^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>HVX?r! | LOCK|k% | $23B | |||
| Incyte Corp
INCY
| LOCK|&WQ%P^R | LOCK|?z | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<RLq&%$ | LOCK|%<R | $16B |
United States